Impact of 10-valent pneumococcal conjugate vaccine on hospital admissions due to pneumonia among children in Nepal

To evaluate the impact of 10-valent pneumococcal conjugate vaccine (PCV10) introduction on hospital admission due to pneumonia among children in Nepal. Hospital records from Siddhi Memorial Hospital, Bhaktapur from 2014 to 2022 were retrospectively analyzed to compare pre-PCV10 (2014–2015) and post-PCV10 (2016–2022) periods. Among 10,897 admitted children, the proportion of pneumonia cases declined from 20.4 % ( n = 429) before the introduction of PCV10 to 10.5 % ( n = 923) after its introduction ( p < 0.001). The adjusted prevalence of pneumonia was 19 % lower in 2016 (aPR 0.81 (95 % CI: 0.64–1.02)) and 69 % lower in 2020 (aPR 0.31 (95 % CI: 0.21–0.45)) among children 2 to 23 months of age. Similarly, aPR reduced from 0.72 (95 % CI: 0.55–0.96) in 2016 to 0.31 (95 % CI 0.17–0.55) in 2020 among children of 24 to 59 months. These findings support PCV10's role in reducing burden of childhood pneumonia in Nepal.

Authors

Institutions

Publication Details

Journal
Vaccine X
Published
2025-12-23
DOI
https://doi.org/10.1016/j.jvacx.2025.100773
Primary Topic
Pneumonia and Respiratory Infections
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of 10-valent pneumococcal conjugate vaccine on hospital admissions due to pneumonia among children in Nepal

Ganendra Bhakta Raya, Bhim Gopal Dhoubhadel, Dhruba Shrestha, Yumiko Hayashi et al.
Vaccine X
Pneumonia and Respiratory Infections
article

Impact of 10-valent pneumococcal conjugate vaccine on hospital admissions due to pneumonia among children in Nepal

Ganendra Bhakta Raya, Bhim Gopal Dhoubhadel, Dhruba Shrestha, Yumiko Hayashi, Koya Ariyoshi, Raj Kumar Shrestha, Konosuke Morimoto, Christopher M. Parry
article en

Abstract

To evaluate the impact of 10-valent pneumococcal conjugate vaccine (PCV10) introduction on hospital admission due to pneumonia among children in Nepal. Hospital records from Siddhi Memorial Hospital, Bhaktapur from 2014 to 2022 were retrospectively analyzed to compare pre-PCV10 (2014–2015) and post-PCV10 (2016–2022) periods. Among 10,897 admitted children, the proportion of pneumonia cases declined from 20.4 % ( n = 429) before the introduction of PCV10 to 10.5 % ( n = 923) after its introduction ( p < 0.001). The adjusted prevalence of pneumonia was 19 % lower in 2016 (aPR 0.81 (95 % CI: 0.64–1.02)) and 69 % lower in 2020 (aPR 0.31 (95 % CI: 0.21–0.45)) among children 2 to 23 months of age. Similarly, aPR reduced from 0.72 (95 % CI: 0.55–0.96) in 2016 to 0.31 (95 % CI 0.17–0.55) in 2020 among children of 24 to 59 months. These findings support PCV10's role in reducing burden of childhood pneumonia in Nepal.

Vaccine XVol. 28
University of Oxford (GB), Nagasaki University (JP)
Good health and well-being
Openalex Percentile: Top 31%
Pneumonia and Respiratory Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Impact of 10-valent pneumococcal conjugate vaccine on hospital admissions due to pneumonia among children in Nepal — Ganendra Bhakta Raya, Bhim Gopal Dhoubhadel, et al. · Vaccine X (2025) | TGRS Research Map | TGRS